Key Calls Jacobson Pharma (2633 HK/BUY/HK$1.46/Target: HK$2.73) Jacobson is a leading generic drugs provider in Hong Kong, with Arsenol potentially being the first FDA-approved drug developed locally. We believe Arsenol could be a game changer for Jacobson, contributing 14%/50% of net profit in FY29/34 upon successful FDA approval in 2028. Its current price implies 8.7x FY26F PE and a 6.9% FY26 dividend yield, and we believe the market has not priced in Arsenol’s value of HK$1.13 per share based...
KEY CALLS Jacobson Pharma (2633 HK/BUY/HK$1.46) Leading generic drug provider in Hong Kong. Jacobson Pharma (Jacobson) is the leading generic drugs provider in Hong Kong with a diversified product portfolio of over 3,000 SKUs and nine PIC/S GMPS-accredited generics manufacturing facilities in Hong Kong. The company has been the largest provider of generic drugs to the Hospital Authority since 2012, which accounted for 48% of Jacobson's FY25 revenue. Eyeing US FDA approval for Oral Arsenic Tri...
VSTECS’ 1H25 revenue/net profit grew 13.6%/34.7% yoy to HK$45,515m/HK$610m respectively, representing 46%/51% of our full-year estimates, thanks to robust growth in enterprise systems and cloud computing as well as strong performances in SEA. The company targets a 20% earnings CAGR in 2025-27, driven by robust growth of its cloud computing systems and SEA expansion. Downgrade to HOLD but raise target price to HK$11.05 based on 12.0x 2025F PE.
KEY HIGHLIGHTS Sector Automobile China’s yoy PV and PEV sales growth returned to positive territory (at +6.2%/+13.5%) in the 33rd week of 2025, as OEMs cut prices again. Geely’s insurance registrations spiked 21% wow during the week, beating our expectation, driven by the blockbuster new model Galaxy A7. However, BYD, Tesla China and Li Auto still posted a yoy sales decline during the week, albeit a wow rebound. Maintain MARKET WEIGHT. Top BUYs: CATL, Geely and Tuopu. Results AAC Technologi...
GREATER CHINA Sector Automobile: Weekly: YOY PV sales growth turns positive on price cuts. Maintain MARKET WEIGHT on the sector. Top BUYs: CATL, Geely and Tuopu. Results AAC Technologies (2018 HK/BUY/HK$43.72/Target: HK$57.70): 1H25: Margins miss due to transition period; meaningful recovery in 2H25. Maintain BUY. AIA Group (1299 HK/BUY/HK$73.45/Target: HK$91.00): 1H25: In-line VONB growth; strong OPAT beat. EVE Energy (300014 HK/HOLD/ Rmb48.07/Target: Rmb50.00): 2Q25: Earnings miss due to lowe...
KEY CALLS 2H25 Outlook Despite a pause in the trade war, we expect tariff rates in the US to be at least 10% higher than pre-liberation levels. As such, we continue to prefer domestic names with minimal US exposure and solid growth potentials in China and Southeast Asia (SEA), such as JBM Healthcare and VSTECS. We are also eyeing names with potential business turnaround, such as Giordano. UPDATES Crystal International (2232 HK/BUY/HK$5.02/Target: HK$6.18) Horizon Robotics (9660 HK/Not Rated/...
GREATER CHINA Strategy Small-Mid Cap Monthly: 2H25 outlook: Eyeing domestic plays and names with potential turnaround. Sector Automobile: Weekly: Is there an Evergrand in the China auto sector? Maintain MARKET WEIGHT on the sector. Top BUYs: Geely and XPeng. Results CSPC Pharmaceutical Group (1093 HK/HOLD/HK$7.62/Target: HK$7.70): 1Q25: Results miss; expects enhanced pipelines to secure major BD deals. Li Auto Inc (2015 HK/BUY/HK$108.20/Target: HK$145.00): 1Q25: Earnings and forward guidance mi...
Key Calls 2H25 Outlook Despite a pause in the trade war, we expect tariff rates in the US to be at least 10% higher than pre-liberation levels. As such, we continue to prefer domestic names with minimal US exposure and solid growth potentials in China and SEA, such as JBM Healthcare and VSTECS. We are also eyeing names with potential business turnaround, such as Giordano. Top pick: JBM (2161 HK). JBM is a leading branded healthcare provider with 95% revenue in Hong Kong and Mainland China...
KEY CALLS Sidestepping Trump’s Tariffs Trump has imposed up to 245% import tariffs on China and 10% tariffs on the rest of the world as the reciprocal tariffs announced on 2 April are put on hold for 90 days from 9 April. While Trump has exempted smartphones, computers and other tech devices from reciprocal tariffs on 11 April, they could be subject to a separate round of “semiconductor tariffs”, which will likely be announced next week. UPDATES Crystal International (2232 HK/BUY/HK$4.46/Tar...
Key Calls Sidestepping Trump’s Tariffs Trump has imposed up to 245% import tariffs on China and 10% tariffs on the rest of the world as the reciprocal tariffs announced on 2 April are put on hold for 90 days from 9 April. While Trump has exempted smartphones, computers and other tech devices from reciprocal tariffs on 11 April, they could be subject to a separate round of “semiconductor tariffs”, which will likely be announced next week. In view of the US’ ever-changing tariff policies, we ...
VSTECS’ 2024 revenue/net profit grew by 20.6%/14.1% yoy to HK$89,086m/HK$1,052m, beating our estimates, thanks to robust growth in enterprise systems, cloud computing and a strong performance in Southeast Asia. Management plans to increase its R&D in AI by 50% in 2025 and targets a 15-20% net profit CAGR in 2025-27. The company targets a 30-35% dividend payout ratio going forward. Maintain BUY and raise target price to HK$6.85 based on 8.0x 2025F PE.
KEY HIGHLIGHTS Results COSCO SHIPPING Ports (1199 HK/BUY/HK$4.78/Target: HK$5.90) CSP’s 2024 core net profit of US$301.8m (+4.9% yoy) was in line with our expectation, at 101.2% of our forecast. The miss at the operating profit level was more than offset by strong JV/associate performance and interest cost savings from debt refinancing. Management guides CSP’s portfolio equity throughput to grow in line with the industry average at a low-single-digit growth rate in 2025. CSP is trading at 7.6x...
GREATER CHINA Results COSCO SHIPPING Ports (1199 HK/BUY/HK$4.78/Target: HK$5.90) 2024: Core earnings in line; expect low single digit throughput growth in 2025. CSPC Innovation Pharmaceutical Co (300765 CH/BUY/Rmb37.00/Target: Rmb50.00) 2024: Smooth progress in R&D promises bright long-term outlook. Hansoh Pharmaceutical Group Company (3692 HK/BUY/HK$20.10/Target:HK$29.00) 2024: Results beat; strong growth momentum continues. Meituan (3690 HK/BUY/HK$167.60/Target: HK$216.00) ...
Key Calls Crystal International (2232 HK) We held an update call with Crystal International (Crystal). It has already achieved its 2H24 target of adding 4,000 workers (vs 70,000 workers as of Jun 24) in 3Q24 and continues to recruit workers in 4Q24, thanks to stronger-than-expected order growth from its key customers, especially Uniqlo and Lululemon. Crystal is Lululemon’s strategic partner and is planning to set up a new factory for Lululemon in Vietnam in view of a solid order growth moment...
KEY HIGHLIGHTS Strategy Small-Mid Cap Monthly Key Calls: Crystal International (2232 HK) -- Stronger order visibility into 2025 for Crystal International, reiterate BUY and raise target price to HK$5.12. Updates: VSTECS Holdings (856 HK/BUY/HK$4.53/Target: HK$5.47) & Texwinca (321 HK/Not Rated/HK$0.91) TRADERS’ CORNER China International Capital (3908 HK): Trading buy range: HK$15.25-15.70 China Mengniu Dairy (2319 HK): Trading buy range: HK$18.06-18.36
GREATER CHINA Strategy Small-Mid Cap Monthly Stronger order visibility into 2025, reiterate BUY on Crystal International and raise target price to HK$5.12. INDONESIA Results Indofood Sukses Makmur (INDF IJ/BUY/Rp7,875/Target: Rp12,000) 3Q24: Ahead of consensus expectation – driven by IFAR. Indofood CBP (ICBP IJ/BUY/Rp12,450/Target: Rp15,000) 3Q24: Strong volume growth; core NPAT in line wit...
SMALL-MID CAP MONTHLY − GREATER CHINA Key Calls Crystal International (2232 HK) We held an update call with Crystal. It has already achieved its 2H24 target of adding 4,000 workers (vs 70,000 workers as of Jun 24) in 3Q24 and continues to recruit workers in 4Q24, thanks to stronger-than-expected order growth from its key customers, especially Uniqlo and Lululemon. Crystal is Lululemon’s strategic partner and is planning to set up a new factory for Lululemon in Vietnam in view of a solid orde...
VSTECS is the eighth-largest IT distributor globally with an established presence in SEA and China. We forecast a three-year net profit CAGR of 9.2% in 2024-26, fuelled by the rising adoption of AI, refresh cycles for consumer electronics and diversifying cloud services. We like VSTECS’ operating efficiency and cash conversion. We expect a dividend yield of 4.4%/5.1% in 2024-25 on solid cash flow generation. Initiate coverage with BUY. Target price: HK$5.47.
KEY HIGHLIGHTS Initiate Coverage VSTECS Holdings (856 HK/BUY/HK$4.46/Target: HK$5.47) VSTECS is the eighth-largest IT distributor globally with an established presence in SEA and China. We forecast a three-year net profit CAGR of 9.2% in 2024-26, fuelled by the rising adoption of AI, refresh cycles for consumer electronics and diversifying cloud services. We like VSTECS’ operating efficiency and cash conversion. We expect a dividend yield of 4.4%/5.1% in 2024-25 on solid cash flow generation...
GREATER CHINA Initiate Coverage VSTECS Holdings (856 HK/BUY/HK$4.46/Target: HK$5.47): Leading IT distributor riding the AI wave. Results Haier Smart Home (6690 HK/BUY/HK$29.80/Target: HK$42.00): 3Q24: Earnings growth driven by efficiency improvement; expect potential tariff hike to have limited impact. Joyson Electronics (600699 CH/BUY/Rmb16.68/Target: Rmb30.00): 3Q24: Earnings in line; maintain BUY with unchanged target price of Rmb30.00. Shenzhen Inovance (300124 CH/HOLD/Rmb56.46/Target: Rmb56...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.